Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2004 Nov;96(11):1477–1491.

The clinical spectrum of amiodarone-associated optic neuropathy.

Lenworth N Johnson 1, Gregory B Krohel 1, Eric R Thomas 1
PMCID: PMC2568612  PMID: 15586652

Abstract

PURPOSE: To describe the clinical spectrum of amiodarone-associated optic neuropathy. METHODS: Observational cases series and review. RESULTS: Of 55 cases, the median interval for onset of optic neuropathy was four months after initiating amiodarone; 88% occurred within 12 months. Seven (13%) patients were asymptomatic. Twenty-two (40%) patients presented with sudden visual loss, while 26 (47%) had insidious loss of vision. Visual acuity ranged from 20/15 to light perception; 10 (18%) patients had legal blindness with visual acuity of 20/200 or worse. Visual field loss was present in 91% of cases. Color vision loss was present in eight (40%) of 20 cases. Optic disc edema was present in 85% of cases, while eight (15%) patients had retrobulbar optic neuropathy, without evidence of disc edema. Optic disc edema resolved over a median time of three months. Five patients had raised intracranial pressure on lumbar puncture. CONCLUSION: We were able to classify amiodarone-associated optic neuropathy into five clinical categories with respect to temporal characteristics and optic nerve appearance: insidious-onset (43%), acute-onset (28%), retrobulbar (13%), increased intracranial pressure (8%), and delayed-progressive onset (8%). Most cases of optic neuropathy commenced within 12 months of initiating amiodarone, with the median onset being four months. Over 10% of patients will have no visual symptoms at the onset. Ophthalmologic examinations within the first 12 months--and particularly within four months of initiating amiodarone--should improve early detection of amiodarone-associated optic neuropathy.

Full text

PDF
1477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson A. B., McAreavey D., Trope G. Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid). Br Heart J. 1980 Apr;43(4):490–491. doi: 10.1136/hrt.43.4.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartolucci J., Ibáez P., Verdugo C., Fuentes R., Arriagada G., Torres J. Neuritis retrobulbar inducida por amiodarona. Caso clínico. Rev Med Chil. 1999 Jul;127(7):827–830. [PubMed] [Google Scholar]
  3. Beck R. W., Savino P. J., Repka M. X., Schatz N. J., Sergott R. C. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology. 1984 Nov;91(11):1334–1337. doi: 10.1016/s0161-6420(84)34146-x. [DOI] [PubMed] [Google Scholar]
  4. Beck R. W., Servais G. E., Hayreh S. S. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology. 1987 Nov;94(11):1503–1508. [PubMed] [Google Scholar]
  5. Behrens M. M. Letter: Optic atrophy in children after diiodohydroxyquin therapy. JAMA. 1974 May 6;228(6):693–694. doi: 10.1001/jama.1974.03230310015005. [DOI] [PubMed] [Google Scholar]
  6. Belec L., Davila G., Bleibel J. M., Azoulay A., Laloun L., Poisson M. Neuropathie optique bilatérale au cours d'un traitemant prolongé par l'amiodarone. Ann Med Interne (Paris) 1992;143(5):349–350. [PubMed] [Google Scholar]
  7. Bockhardt H., Drenckhahn D., Lüllmann-Rauch R. Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978 Jul 17;207(2):91–96. doi: 10.1007/BF00414306. [DOI] [PubMed] [Google Scholar]
  8. Boghen D. R., Glaser J. S. Ischaemic optic neuropathy. The clinical profile and history. Brain. 1975 Dec;98(4):689–708. doi: 10.1093/brain/98.4.689. [DOI] [PubMed] [Google Scholar]
  9. Burde R. M. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993 Dec 15;116(6):759–764. doi: 10.1016/s0002-9394(14)73478-6. [DOI] [PubMed] [Google Scholar]
  10. Castells David D., Teitelbaum Bruce A., Tresley David J. Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy. Optometry. 2002 Feb;73(2):113–121. [PubMed] [Google Scholar]
  11. Charness M. E., Morady F., Scheinman M. M. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984 May;34(5):669–671. doi: 10.1212/wnl.34.5.669. [DOI] [PubMed] [Google Scholar]
  12. Cordon Lopez A., Muñoz Lopez A., Fernandez Jimenez S., Ruiz de Elvira M. J. Acute intracranial hypertension during amiodarone infusion. Crit Care Med. 1985 Aug;13(8):688–689. doi: 10.1097/00003246-198508000-00018. [DOI] [PubMed] [Google Scholar]
  13. Costa-Jussà F. R., Jacobs J. M. The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. Brain. 1985 Sep;108(Pt 3):735–752. doi: 10.1093/brain/108.3.735. [DOI] [PubMed] [Google Scholar]
  14. D'Amico D. J., Kenyon K. R., Ruskin J. N. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981 Feb;99(2):257–261. doi: 10.1001/archopht.1981.03930010259007. [DOI] [PubMed] [Google Scholar]
  15. DeWitt Christine A., Johnson Lenworth N., Schoenleber Dana B., Hainsworth Dean P., Madsen Richard W. Visual function in patients with optic nerve pallor (optic atrophy). J Natl Med Assoc. 2003 May;95(5):394–397. [PMC free article] [PubMed] [Google Scholar]
  16. Dewachter A., Lievens H. Amiodarone and optic neuropathy. Bull Soc Belge Ophtalmol. 1988;227:47–50. [PubMed] [Google Scholar]
  17. Duff G. R., Fraser A. G. Impairment of colour vision associated with amiodarone keratopathy. Acta Ophthalmol (Copenh) 1987 Feb;65(1):48–52. doi: 10.1111/j.1755-3768.1987.tb08490.x. [DOI] [PubMed] [Google Scholar]
  18. Eryilmaz T., Atilla H., Batioglu F., Günalp I. Amiodarone-related optic neuropathy. Jpn J Ophthalmol. 2000 Sep-Oct;44(5):565–568. doi: 10.1016/s0021-5155(00)00216-1. [DOI] [PubMed] [Google Scholar]
  19. Feiner L. A., Younge B. R., Kazmier F. J., Stricker B. H., Fraunfelder F. T. Optic neuropathy and amiodarone therapy. Mayo Clin Proc. 1987 Aug;62(8):702–717. doi: 10.1016/s0025-6196(12)65224-0. [DOI] [PubMed] [Google Scholar]
  20. Feit R. H., Tomsak R. L., Ellenberger C., Jr Structural factors in the pathogenesis of ischemic optic neuropathy. Am J Ophthalmol. 1984 Jul 15;98(1):105–108. doi: 10.1016/0002-9394(84)90196-x. [DOI] [PubMed] [Google Scholar]
  21. Ferreiro J. L., Isern Longares J. A., Ramón Moya A. F. Neuropatía óptica por amiodarona. Neurologia. 1990 May;5(5):160–163. [PubMed] [Google Scholar]
  22. Fikkers B. G., Bogousslavsky J., Regli F., Glasson S. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1986 May;49(5):606–606. doi: 10.1136/jnnp.49.5.606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. François J. Cornea verticillata. Bull Soc Belge Ophtalmol. 1968;150:656–670. [PubMed] [Google Scholar]
  24. Germain Dominique P. Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs. 2002 Oct;11(10):1467–1476. doi: 10.1517/13543784.11.10.1467. [DOI] [PubMed] [Google Scholar]
  25. Ghosh M., McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol. 1984 Jun;19(4):178–186. [PubMed] [Google Scholar]
  26. Gibson J. M., Fielder A. R., Garner A., Millac P. Severe ocular side effects of perhexilene maleate: case report. Br J Ophthalmol. 1984 Aug;68(8):553–560. doi: 10.1136/bjo.68.8.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gittinger J. W., Jr, Asdourian G. K. Papillopathy caused by amiodarone. Arch Ophthalmol. 1987 Mar;105(3):349–351. doi: 10.1001/archopht.1987.01060030069028. [DOI] [PubMed] [Google Scholar]
  28. Gobbelé R., Dahlke C., Mull M., Schwarz M. Amiodaron-induzierte bilaterale Optikusneuropathie. Eine Kasuistik. Nervenarzt. 1999 Jun;70(6):560–565. doi: 10.1007/s001150050481. [DOI] [PubMed] [Google Scholar]
  29. Grogan W. A., Narkun D. M. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1987 May;50(5):651–651. doi: 10.1136/jnnp.50.5.651-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Guyer D. R., Miller N. R., Auer C. L., Fine S. L. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol. 1985 Aug;103(8):1136–1142. doi: 10.1001/archopht.1985.01050080048018. [DOI] [PubMed] [Google Scholar]
  31. Harris L., McKenna W. J., Rowland E., Holt D. W., Storey G. C., Krikler D. M. Side effects of long-term amiodarone therapy. Circulation. 1983 Jan;67(1):45–51. doi: 10.1161/01.cir.67.1.45. [DOI] [PubMed] [Google Scholar]
  32. Hattenhauer M. G., Leavitt J. A., Hodge D. O., Grill R., Gray D. T. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997 Jan;123(1):103–107. doi: 10.1016/s0002-9394(14)70999-7. [DOI] [PubMed] [Google Scholar]
  33. Hayreh S. S. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye (Lond) 1990;4(Pt 1):25–41. doi: 10.1038/eye.1990.4. [DOI] [PubMed] [Google Scholar]
  34. Hayreh S. S., Joos K. M., Podhajsky P. A., Long C. R. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994 Dec 15;118(6):766–780. doi: 10.1016/s0002-9394(14)72557-7. [DOI] [PubMed] [Google Scholar]
  35. Holt D. W., Tucker G. T., Jackson P. R., Storey G. C. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct;106(4 Pt 2):840–847. doi: 10.1016/0002-8703(83)90006-6. [DOI] [PubMed] [Google Scholar]
  36. Honegger U. E., Scuntaro I., Wiesmann U. N. Vitamin E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochem Pharmacol. 1995 Jun 16;49(12):1741–1745. doi: 10.1016/0006-2952(95)00100-e. [DOI] [PubMed] [Google Scholar]
  37. Ikäheimo Kirsi, Kettunen Raimo, Mäntyjärvi Maija. Visual functions and adverse ocular effects in patients with amiodarone medication. Acta Ophthalmol Scand. 2002 Feb;80(1):59–63. doi: 10.1034/j.1600-0420.2002.800112.x. [DOI] [PubMed] [Google Scholar]
  38. Jacobs J. M., Costa-Jussà F. R. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man. Brain. 1985 Sep;108(Pt 3):753–769. doi: 10.1093/brain/108.3.753. [DOI] [PubMed] [Google Scholar]
  39. Jacobson D. M., Vierkant R. A., Belongia E. A. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol. 1997 Nov;115(11):1403–1407. doi: 10.1001/archopht.1997.01100160573008. [DOI] [PubMed] [Google Scholar]
  40. Jirásková N., Rozsíval P., Hobza V. Amiodaronová neuropatie optiku z pohledu neurooftalmologa. Cesk Slov Oftalmol. 1996 Oct;52(5):308–318. [PubMed] [Google Scholar]
  41. Johnson L. N., Arnold A. C. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994 Mar;14(1):38–44. [PubMed] [Google Scholar]
  42. Johnson L. N., Guy M. E., Krohel G. B., Madsen R. W. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000 Mar;107(3):521–526. doi: 10.1016/s0161-6420(99)00133-5. [DOI] [PubMed] [Google Scholar]
  43. Johnson L. N., Krohel G. B., Allen S. D., Mozayeni R. Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. J Natl Med Assoc. 1996 Jun;88(6):369–373. [PMC free article] [PubMed] [Google Scholar]
  44. Johnson L. N., Krohel G. B., Madsen R. W., March G. A., Jr The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri) Ophthalmology. 1998 Dec;105(12):2313–2317. doi: 10.1016/S0161-6420(98)91234-9. [DOI] [PubMed] [Google Scholar]
  45. Johnson L. N., Kuo H. C., Arnold A. C. HLA-A29 as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993 Apr 15;115(4):540–542. doi: 10.1016/s0002-9394(14)74462-9. [DOI] [PubMed] [Google Scholar]
  46. Kaplan L. J., Cappaert W. E. Amiodarone keratopathy. Correlation to dosage and duration. Arch Ophthalmol. 1982 Apr;100(4):601–602. doi: 10.1001/archopht.1982.01030030603011. [DOI] [PubMed] [Google Scholar]
  47. Krieg P., Schipper I. Bilaterale Optikusneuropathie nach Amiodarone-Therapie. Klin Monbl Augenheilkd. 1992 Feb;200(2):128–132. doi: 10.1055/s-2008-1045725. [DOI] [PubMed] [Google Scholar]
  48. Kristin N., Ulbig M. Akutes Papillenödem. 69-jähriger Patient mit bilateralem akutem Papillenödem. Ophthalmologe. 2001 Feb;98(2):212–213. doi: 10.1007/s003470170187. [DOI] [PubMed] [Google Scholar]
  49. Leifert D., Hansen L. L., Gerling J. Amiodaron-Optikusneuropathie: ein eigenständiges Krankheitsbild? Drei Patienten mit beidseitiger Optikusneuropathie. Klin Monbl Augenheilkd. 2000 Sep;217(3):171–177. doi: 10.1055/s-2000-10341. [DOI] [PubMed] [Google Scholar]
  50. Macaluso D. C., Shults W. T., Fraunfelder F. T. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol. 1999 May;127(5):610–612. doi: 10.1016/s0002-9394(99)00016-1. [DOI] [PubMed] [Google Scholar]
  51. Manolis A. S., Tordjman T., Mack K. D., Estes N. A., 3rd Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Arch Intern Med. 1987 Oct;147(10):1805–1809. [PubMed] [Google Scholar]
  52. Mansour A. M., Puklin J. E., O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol. 1988 Dec;8(4):231–237. [PubMed] [Google Scholar]
  53. Meier C., Kauer B., Müller U., Ludin H. P. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol. 1979 Jan 5;220(4):231–239. doi: 10.1007/BF00314147. [DOI] [PubMed] [Google Scholar]
  54. Mindel J. M. Amiodarone and optic neuropathy--a medicolegal issue. Surv Ophthalmol. 1998 Jan-Feb;42(4):358–359. doi: 10.1016/s0039-6257(97)00120-3. [DOI] [PubMed] [Google Scholar]
  55. Mojon Daniel S., Hedges Thomas R., 3rd, Ehrenberg Bruce, Karam Emely Z., Goldblum David, Abou-Chebl Alex, Gugger Matthias, Mathis Johannes. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol. 2002 May;120(5):601–605. doi: 10.1001/archopht.120.5.601. [DOI] [PubMed] [Google Scholar]
  56. Moorthy R. S., Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol. 1999 Dec;10(6):438–446. doi: 10.1097/00055735-199912000-00012. [DOI] [PubMed] [Google Scholar]
  57. Mäntyjärvi M., Tuppurainen K., Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998 Jan-Feb;42(4):360–366. doi: 10.1016/s0039-6257(97)00118-5. [DOI] [PubMed] [Google Scholar]
  58. Nagra P. K., Foroozan R., Savino P. J., Castillo I., Sergott R. C. Amiodarone induced optic neuropathy. Br J Ophthalmol. 2003 Apr;87(4):420–422. doi: 10.1136/bjo.87.4.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Nazarian S. M., Jay W. M. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuroophthalmol. 1988 Mar;8(1):25–28. [PubMed] [Google Scholar]
  60. Newman Nancy J., Scherer Roberta, Langenberg Patricia, Kelman Shalom, Feldon Steven, Kaufman David, Dickersin Kay, Ischemic Optic Neuropathy Decompression Trial Research Group The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002 Sep;134(3):317–328. doi: 10.1016/s0002-9394(02)01639-2. [DOI] [PubMed] [Google Scholar]
  61. Orlando R. G., Dangel M. E., Schaal S. F. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 1984 Oct;91(10):1184–1187. doi: 10.1016/s0161-6420(84)34165-3. [DOI] [PubMed] [Google Scholar]
  62. Paillous N., Fery-Forgues S. Is there a link between the phototoxic or antioxidant properties of amiodarone, an antiarrhythmic drug, and its lipophilic character? Biochem Pharmacol. 1994 Aug 30;48(5):851–857. doi: 10.1016/0006-2952(94)90354-9. [DOI] [PubMed] [Google Scholar]
  63. Palimar P., Cota N. Bilateral anterior ischaemic optic neuropathy following amiodarone. Eye (Lond) 1998;12(Pt 5):894–896. doi: 10.1038/eye.1998.227. [DOI] [PubMed] [Google Scholar]
  64. Pellissier J. F., Pouget J., Cros D., De Victor B., Serratrice G., Toga M. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci. 1984 Feb;63(2):251–266. doi: 10.1016/0022-510x(84)90200-4. [DOI] [PubMed] [Google Scholar]
  65. Polak B. C., Tutein Nolthenius P. A., Rietveld E. Slechtziendheid door opticusneuropathie bij 2 patiënten die amiodaron respectievelijk ethambutol en isoniazide gebruikten. Ned Tijdschr Geneeskd. 2001 May 12;145(19):922–926. [PubMed] [Google Scholar]
  66. Pollak P. T., Bouillon T., Shafer S. L. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 2000 Jun;67(6):642–652. doi: 10.1067/mcp.2000.107047. [DOI] [PubMed] [Google Scholar]
  67. Raeder E. A., Podrid P. J., Lown B. Side effects and complications of amiodarone therapy. Am Heart J. 1985 May;109(5 Pt 1):975–983. doi: 10.1016/0002-8703(85)90238-8. [DOI] [PubMed] [Google Scholar]
  68. Rennie I. G. Clinically important ocular reactions to systemic drug therapy. Drug Saf. 1993 Sep;9(3):196–211. doi: 10.2165/00002018-199309030-00005. [DOI] [PubMed] [Google Scholar]
  69. Repka M. X., Savino P. J., Schatz N. J., Sergott R. C. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol. 1983 Oct;96(4):478–483. doi: 10.1016/s0002-9394(14)77911-5. [DOI] [PubMed] [Google Scholar]
  70. Sedwick L. A. Getting to the heart of visual loss: when cardiac medication may be dangerous to the optic nerves. Surv Ophthalmol. 1992 Mar-Apr;36(5):366–372. doi: 10.1016/0039-6257(92)90114-9. [DOI] [PubMed] [Google Scholar]
  71. Seemongal-Dass R. R., Spencer S. R. Bilateral optic neuropathy linked with amiodarone. Eye (Lond) 1998;12(Pt 3A):474–477. doi: 10.1038/eye.1998.108. [DOI] [PubMed] [Google Scholar]
  72. Shukla R., Jowett N. I., Thompson D. R., Pohl J. E. Side effects with amiodarone therapy. Postgrad Med J. 1994 Jul;70(825):492–498. doi: 10.1136/pgmj.70.825.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Singh B. N. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol. 1997 Jul;20(7):608–618. doi: 10.1002/clc.4960200706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Somani P. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies. J Clin Pharmacol. 1989 May;29(5):405–412. doi: 10.1002/j.1552-4604.1989.tb03352.x. [DOI] [PubMed] [Google Scholar]
  75. Speicher M. A., Goldman M. H., Chrousos G. A. Amiodarone optic neuropathy without disc edema. J Neuroophthalmol. 2000 Sep;20(3):171–172. doi: 10.1097/00041327-200020030-00007. [DOI] [PubMed] [Google Scholar]
  76. Sreih A. G., Schoenfeld M. H., Marieb M. A. Optic neuropathy following amiodarone therapy. Pacing Clin Electrophysiol. 1999 Jul;22(7):1108–1110. doi: 10.1111/j.1540-8159.1999.tb00582.x. [DOI] [PubMed] [Google Scholar]
  77. Uebermuth C. A., Gerke E. Zunächst einseitige, später beidseitige Optikopathie. Amiodaron als Ursache? Ophthalmologe. 2002 Jun;99(6):470–473. doi: 10.1007/s003470100551. [DOI] [PubMed] [Google Scholar]
  78. Van Zandijcke M., Dewachter A. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry. 1986 Dec;49(12):1463–1464. doi: 10.1136/jnnp.49.12.1463-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Vereckei A., Blazovics A., Gyorgy I., Feher E., Toth M., Szenasi G., Zsinka A., Foldiak G., Feher J. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol. 1993 Apr;4(2):161–177. doi: 10.1111/j.1540-8167.1993.tb01220.x. [DOI] [PubMed] [Google Scholar]
  80. Vorperian V. R., Havighurst T. C., Miller S., January C. T. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997 Sep;30(3):791–798. doi: 10.1016/s0735-1097(97)00220-9. [DOI] [PubMed] [Google Scholar]
  81. Vrobel T. R., Miller P. E., Mostow N. D., Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis. 1989 May-Jun;31(6):393–426. doi: 10.1016/0033-0620(89)90016-9. [DOI] [PubMed] [Google Scholar]
  82. Weger Martin, Haas Anton, Stanger Olaf, El-Shabrawi Yosuf, Temmel Werner, Maier Richard, Berghold Andrea, Haller-Schober Eva-Maria. Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy. Ophthalmology. 2002 Apr;109(4):749–752. doi: 10.1016/s0161-6420(01)01031-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES